News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
693,168 Results
Type
Article (39441)
Company Profile (322)
Press Release (653405)
Section
Business (206244)
Career Advice (2003)
Deals (35683)
Drug Delivery (85)
Drug Development (81870)
Employer Resources (170)
FDA (16130)
Job Trends (14941)
News (348398)
Policy (32643)
Tag
Academia (2538)
Alliances (49736)
Alzheimer's disease (1234)
Approvals (16063)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11633)
Biotechnology (231)
Breast cancer (121)
Cancer (1087)
Cardiovascular disease (98)
Career advice (1670)
Cell therapy (234)
Clinical research (65106)
Collaboration (391)
Compensation (200)
COVID-19 (2540)
C-suite (96)
Data (1126)
Diabetes (152)
Diagnostics (6149)
Earnings (85735)
Employer resources (148)
Events (111552)
Executive appointments (311)
FDA (16664)
Funding (350)
Gene therapy (177)
GLP-1 (584)
Government (4341)
Healthcare (18718)
Infectious disease (2625)
Inflammatory bowel disease (106)
Interviews (312)
IPO (16480)
Job creations (3670)
Job search strategy (1426)
Layoffs (416)
Legal (7879)
Lung cancer (170)
Manufacturing (177)
Medical device (13184)
Medtech (13189)
Mergers & acquisitions (19279)
Metabolic disorders (403)
Neuroscience (1513)
NextGen Class of 2024 (6525)
Non-profit (4478)
Northern California (1480)
Obesity (232)
Opinion (179)
Patents (102)
People (56942)
Phase I (20250)
Phase II (28727)
Phase III (21299)
Pipeline (455)
Postmarket research (2559)
Preclinical (8623)
Radiopharmaceuticals (244)
Rare diseases (219)
Real estate (5979)
Regulatory (21686)
Research institute (2321)
Resumes & cover letters (349)
Southern California (1303)
Startups (3608)
United States (13582)
Vaccines (551)
Weight loss (168)
Date
Today (131)
Last 7 days (855)
Last 30 days (3820)
Last 365 days (35985)
2024 (32988)
2023 (40472)
2022 (51634)
2021 (56248)
2020 (54475)
2019 (46903)
2018 (35317)
2017 (32507)
2016 (31947)
2015 (38017)
2014 (31844)
2013 (26766)
2012 (28941)
2011 (29608)
2010 (27666)
Location
Africa (723)
Arizona (194)
Asia (38045)
Australia (6170)
California (3334)
Canada (1289)
China (250)
Colorado (146)
Connecticut (154)
Europe (82241)
Florida (462)
Georgia (116)
Illinois (342)
Indiana (196)
Kansas (96)
Maryland (581)
Massachusetts (2639)
Michigan (157)
Minnesota (274)
New Jersey (957)
New York (961)
North Carolina (744)
Northern California (1480)
Ohio (139)
Pennsylvania (844)
South America (1104)
Southern California (1303)
Texas (468)
Utah (90)
Washington State (363)
693,168 Results for "clover biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults
Clover Biopharmaceuticals, Ltd. announced positive preliminary immunogenicity and safety data in the older adult & elderly cohort from its Phase Ⅰ trial evaluating SCB-1019 – the company’s bivalent RSV prefusion-stabilized F -Trimer subunit vaccine candidate – which is based on Clover’s Trimer-Tag vaccine technology platform.
June 18, 2024
·
5 min read
Drug Development
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
Clover Biopharmaceuticals, Ltd. announced positive preliminary immunogenicity and safety data in the initial young adult cohort from its Phase I trial evaluating SCB-1019 – the company’s bivalent RSV prefusion-stabilized F -Trimer subunit vaccine candidate – which is based on Clover’s Trimer-Tag vaccine technology platform.
April 8, 2024
·
5 min read
Press Releases
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK’s AREXVY
October 29, 2024
·
5 min read
Business
Clover Health to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report fourth quarter and full year 2023 financial results after market close on Tuesday, March 12, 2024.
February 26, 2024
·
1 min read
Press Releases
Clover Health to Participate in Upcoming 2024 Wells Fargo Healthcare Conference
August 23, 2024
·
1 min read
Drug Development
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
Clover Biopharmaceuticals, Ltd. today announced that enrollment of the first participants has been completed in a Phase Ⅰ first-in-human study evaluating the company’s RSV PreF-Trimer subunit vaccine candidate (SCB-1019), which is based on Clover’s Trimer-Tag vaccine technology platform.
December 12, 2023
·
3 min read
Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil
Clover Biopharmaceuticals, Ltd. announced the company completes the Biologic License Application submission for its seasonal influenza vaccine to Brazilian Health Regulatory Agency.
November 6, 2023
·
3 min read
Clover Health to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced that its CEO, Andrew Toy, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 12:00 p.m. Eastern Time.
December 18, 2023
·
1 min read
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197) today announced the launch of AdimFlu-S (QIS) in mainland China, where it is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older.
September 11, 2023
·
4 min read
Drug Development
Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)
Clover Biopharmaceuticals, Ltd., a global commercial-stage biotechnology company, announced positive preliminary safety, efficacy and pharmacokinetics data in a Phase Ⅰ clinical trial evaluating SCB-219M, an innovative thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein produced from CHO cells, for the treatment of cancer patients with chemotherapy-induced thrombocytopenia.
December 28, 2023
·
6 min read
1 of 69,317
Next
